Ginkgo

Single dose oral gabapentin for established acute postoperative pain in adults.

DSpace/Manakin Repository

Straube, Sebastian; Derry, Sheena; Moore, R. Andrew; Wiffen, Philip J.; McQuay, Henry J. (2010): Single dose oral gabapentin for established acute postoperative pain in adults. - Cochrane database of systematic reviews (Online); , No. 5-22.

Verlinken Sie auf bzw. zitieren Sie dieses Dokument mit der folgenden permanenten URL:
bookmark http://resolver.sub.uni-goettingen.de/purl?gs-1/6214

Files in this item

Files Size Format Beschreibung Version
closed accessStraube.pdf 281.6Kb PDF Keine Beschreibung publishedVersion
 
 

Verlagspublikation: 10.1002/14651858.CD008183.pub2

 
Author: Straube, Sebastian; Derry, Sheena; Moore, R. Andrew; Wiffen, Philip J.; McQuay, Henry J.
Abstract: BACKGROUND: Gabapentin is an antiepileptic drug, also used in the treatment of neuropathic pain, which is the subject of a Cochrane review, currently under revision. Its efficacy in treating established acute postoperative pain has not been demonstrated. OBJECTIVES: To assess the efficacy and safety of single dose oral gabapentin compared with placebo in established acute postoperative pain using methods that permit comparison with other analgesics. SEARCH STRATEGY: We searched Cochrane CENTRAL, MEDLINE, EMBASE, and the Oxford Pain Relief Database. Additional studies were sought from reference lists of retrieved articles and reviews. Clinical trials databases were searched for unpublished studies; clinical trial reports of several unpublished studies have been made public following litigation in the US. SELECTION CRITERIA: Single oral dose, randomised, double-blind, placebo-controlled trials of gabapentin for relief of established moderate to severe postoperative pain in adults. DATA COLLECTION AND ANALYSIS: Studies were assessed for methodological quality and data extracted by two review authors independently. Numbers of participants with at least 50% of maximum possible total pain relief (TOTPAR) or summed pain intensity difference (SPID) with gabapentin or placebo were calculated and used to derive relative benefit (RB) or risk (RR), and number-needed-to-treat-to-benefit (NNT). Numbers of participants using rescue medication, and time to its use, were sought as additional measures of efficacy. Information on adverse events and withdrawals was collected. MAIN RESULTS: Four unpublished studies met inclusion criteria; in three, participants had pain following dental surgery, and one followed major orthopaedic surgery; 177 participants were treated with a single dose of gabapentin 250 mg, 21 with gabapentin 500 mg, and 172 with placebo. At least 50% pain relief over 6 hours was achieved by 15% with gabapentin 250 mg and 5% with placebo; giving a RB of 2.5 (95% CI 1.2 to 5.0) and an NNT of 11 (6.4 to 35). Significantly fewer participants needed rescue medication within 6 hours with gabapentin 250 mg than with placebo; NNT to prevent use 5.8. About one third of participants reported adverse events with both gabapentin 250 mg and placebo. No serious adverse events occurred with gabapentin. AUTHORS' CONCLUSIONS: Gabapentin 250 mg is statistically superior to placebo in the treatment of established acute postoperative pain, but the NNT of 11 for at least 50% pain relief over 6 hours with gabapentin 250 mg is of limited clinical value and inferior to commonly used analgesics. Gabapentin 250 mg is not clinically useful as a stand-alone analgesic in established acute postoperative pain, though this is probably the first demonstration of analgesic effect of an antiepileptic in established acute pain.
URI: http://resolver.sub.uni-goettingen.de/purl?gs-1/6214
Date: 2010

The following license files are associated with this item:

Share on:

This item appears in the following Collection(s)

Show full item record

Search DSpace

Advanced Search

Browse

My Account

Infos & Hilfe


Login: ?

GWDG-Benutzername ist der Namensteil uname von ihrer E-Mail-Adresse uname@gwdg.de oder uname@med.uni-goettingen.de

Das Passwort ist Ihr Passwort bei der GWDG.